Vaprisol Approval History

• FDA approved: Yes (First approved December 29th, 2005)
• Brand name: Vaprisol
• Generic name: conivaptan hydrochloride
• Company: Astellas Pharma US, Inc.
• Treatment for: Hyponatremia

Vaprisol (conivaptan hydrochloride injection) is an arginine vasopressin antagonist for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.

FDA Approval History for Vaprisol

Date	Article
Oct 22, 2008	FDA Approves Astellas' Vaprisol (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Mar  2, 2007	FDA Approves Astellas' Vaprisol for the Treatment of Hypervolemic Hyponatremia
Dec 29, 2005	Vaprisol Astellas Pharma US, Inc. - Treatment for Euvolemic Hyponatremia
Dec  1, 2004	FDA Issues Approvable Letter for Yamanouchi's Investigational Hyponatremia Treatment Conivaptan Hydrochloride Injection
Feb  2, 2004	Yamanouchi Pharma America Submits New Drug Application to the FDA for Conivaptan Hydrochloride to treat Hyponatremia

See also...

Vaprisol (conivaptan hydrochloride) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.